Eve Gallop‐Evans

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial

Peter Hoskin, Amy A. Kirkwood, Bilyana Popova et al. · The Lancet Oncology · 2014 · 244 citations

Medicine, Oncology, Radiation Oncology +7

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Myron S. Czuczman, Luis Fayad, Vincent Delwail et al. · Blood · 2012 · 125 citations · Full text

Life Sciences, Immunology, Oncology +9

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

John F. Seymour, Robert Marcus, Andrew Davies et al. · Haematologica · 2018 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial

Peter Hoskin, B. Popova, Oliver Schofield et al. · The Lancet Oncology · 2021 · 108 citations · Full text

Medicine, Oncology, Radiation Oncology +8